Summary of Study ST002063

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001306. The data can be accessed directly via it's Project DOI: 10.21228/M8WT4R This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002063
Study TitleIntravenous lipopolysaccharide infusion and the bovine metabolome
Study TypeMS plasma lipidomics and metabolomics
Study SummaryThe effects of lipopolysaccharides (i.e., endotoxin; LPS) on metabolism are poorly defined in lactating dairy cattle experiencing hyperlipidemia. Our objective was to explore the effects of acute intravenous LPS administration on metabolism in late-lactation Holstein cows experiencing hyperlipidemia. Ten non-pregnant lactating Holstein cows (273 ± 35 d in milk) were administered a single bolus of saline (3 mL of saline; n = 5) or LPS (0.375 μg of LPS/kg of body weight; n = 5). Simultaneously, cows were intravenously infused a triglyceride emulsion and fasted for 16 h to induce hyperlipidemia in an attempt to model the periparturient period. Blood was sampled at routine intervals. Changes in circulating total fatty acid concentrations and inflammatory parameters were measured. Plasma samples were analyzed using untargeted lipidomics and metabolomics. Endotoxin increased circulating serum amyloid A, LPS-binding protein, and cortisol concentrations. Endotoxin administration decreased plasma lysophosphatidylcholine (LPC) concentrations and increased select plasma ceramide concentrations. These outcomes suggest modulation of the immune response and insulin action. Lipopolysaccharide decreased the ratio of phosphatidylcholine to phosphatidylethanomanine, which potentially indicate a decrease in the hepatic activation of phosphatidylethanolamine N-methyltransferase and triglyceride export. Endotoxin administration also increased plasma concentrations of pyruvic and lactic acids, and decreased plasma citric acid concentrations, which implicate the upregulation of glycolysis and downregulation of the citric acid cycle (i.e., the Warburg effect), potentially in leukocytes. Acute intravenous LPS administration decreased circulating LPC concentrations, modified ceramide and glycerophospholipid concentrations, and influenced intermediary metabolism in dairy cows experiencing hyperlipidemia.
Institute
Cornell University
DepartmentAnimal Science
LaboratoryMcFadden lab
Last NameJavaid
First NameAwais
Address400 Warren Rd, Ithaca, New York, 14850, USA
Emailaj366@cornell.edu
Phone6072287246
Submit Date2022-01-09
Raw Data AvailableYes
Raw Data File Type(s)mzXML
Analysis Type DetailLC-MS
Release Date2022-06-30
Release Version1
Awais Javaid Awais Javaid
https://dx.doi.org/10.21228/M8WT4R
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001306
Project DOI:doi: 10.21228/M8WT4R
Project Title:Intravenous lipopolysaccharide infusion and the bovine metabolome
Project Type:MS lipidomics and metabolomics
Project Summary:The effects of lipopolysaccharides (i.e., endotoxin; LPS) on metabolism are poorly defined in lactating dairy cattle experiencing hyperlipidemia. Our objective was to explore the effects of acute intravenous LPS administration on metabolism in late-lactation Holstein cows experiencing hyperlipidemia. Ten non-pregnant lactating Holstein cows (273 ± 35 d in milk) were administered a single bolus of saline (3 mL of saline; n = 5) or LPS (0.375 μg of LPS/kg of body weight; n = 5). Simultaneously, cows were intravenously infused a triglyceride emulsion and fasted for 16 h to induce hyperlipidemia in an attempt to model the periparturient period. Blood was sampled at routine intervals. Changes in circulating total fatty acid concentrations and inflammatory parameters were measured. Plasma samples were analyzed using untargeted lipidomics and metabolomics. Endotoxin increased circulating serum amyloid A, LPS-binding protein, and cortisol concentrations. Endotoxin administration decreased plasma lysophosphatidylcholine (LPC) concentrations and increased select plasma ceramide concentrations. These outcomes suggest modulation of the immune response and insulin action. Lipopolysaccharide decreased the ratio of phosphatidylcholine to phosphatidylethanomanine, which potentially indicate a decrease in the hepatic activation of phosphatidylethanolamine N-methyltransferase and triglyceride export. Endotoxin administration also increased plasma concentrations of pyruvic and lactic acids, and decreased plasma citric acid concentrations, which implicate the upregulation of glycolysis and downregulation of the citric acid cycle (i.e., the Warburg effect), potentially in leukocytes. Acute intravenous LPS administration decreased circulating LPC concentrations, modified ceramide and glycerophospholipid concentrations, and influenced intermediary metabolism in dairy cows experiencing hyperlipidemia.
Institute:Animal Science
Department:Animal Science
Laboratory:McFadden lab
Last Name:Javaid
First Name:Awais
Address:400 Warren Rd, Ithaca, New York, 14850, USA
Email:aj366@cornell.edu
Phone:6072287246
Funding Source:Agriculture and Food Research Initiative grant no. 2018-67015-27548

Subject:

Subject ID:SU002145
Subject Type:Mammal
Subject Species:Bos taurus
Taxonomy ID:9913
Genotype Strain:Holstein dairy cows
Age Or Age Range:4- 5 years
Weight Or Weight Range:733-797
Gender:Female
Animal Housing:Tie stall
Animal Feed:TMR Ad lib
Animal Water:Ad libitum
Animal Inclusion Criteria:lactation stage, Days in milk

Factors:

Subject type: Mammal; Subject species: Bos taurus (Factor headings shown in green)

mb_sample_id local_sample_id Time Treatment Category
SA194101233-10336_CON-IL_12.raw12 CON Lipidomics
SA194102234-9855_CON-IL_12.raw12 CON Lipidomics
SA194103231-9852_CON-IL_12.raw12 CON Lipidomics
SA194104230-9609_CON-IL_12.raw12 CON Lipidomics
SA194105232-9610_CON-IL_12.raw12 CON Lipidomics
SA194106238-9785_LPS-IL_12.raw12 LPS Lipidomics
SA194107237-10008_LPS-IL_12.raw12 LPS Lipidomics
SA194108235-10218_LPS-IL_12.raw12 LPS Lipidomics
SA194109239-10103_LPS-IL_12.raw12 LPS Lipidomics
SA194110236-8473_LPS-IL_12.raw12 LPS Lipidomics
SA194111241-9852_CON-IL_16.raw16 CON Lipidomics
SA194112240-9609_CON-IL_16.raw16 CON Lipidomics
SA194113244-9855_CON-IL_16.raw16 CON Lipidomics
SA194114242-9610_CON-IL_16.raw16 CON Lipidomics
SA194115243-10336_CON-IL_16.raw16 CON Lipidomics
SA1941169609CON-IL-16_NEG.raw16 CON Metabolomics
SA1941179852CON-IL-16_NEG.raw16 CON Metabolomics
SA1941189855CON-IL-16_NEG.raw16 CON Metabolomics
SA19411910336CON-IL-16_NEG.raw16 CON Metabolomics
SA1941209610CON-IL-16_NEG.raw16 CON Metabolomics
SA194121249-10103_LPS-IL_16.raw16 LPS Lipidomics
SA194122245-10218_LPS-IL_16.raw16 LPS Lipidomics
SA194123246-8473_LPS-IL_16.raw16 LPS Lipidomics
SA194124248-9785_LPS-IL_16.raw16 LPS Lipidomics
SA194125247-10008_LPS-IL_16.raw16 LPS Lipidomics
SA19412610218LPS-IL-16_NEG.raw16 LPS Metabolomics
SA19412710103LPS-IL-16_NEG.raw16 LPS Metabolomics
SA1941288473LPS-IL-16_NEG.raw16 LPS Metabolomics
SA1941299785LPS-IL-16_NEG.raw16 LPS Metabolomics
SA19413010008LPS-IL-16_NEG.raw16 LPS Metabolomics
SA194131251-9852_CON-IL_24.raw24 CON Lipidomics
SA194132254-9855_CON-IL_24.raw24 CON Lipidomics
SA194133250-9609_CON-IL_24.raw24 CON Lipidomics
SA194134253-10336_CON-IL_24.raw24 CON Lipidomics
SA194135252-9610_CON-IL_24.raw24 CON Lipidomics
SA194136257-10008_LPS-IL_24.raw24 LPS Lipidomics
SA194137259-10103_LPS-IL_24.raw24 LPS Lipidomics
SA194138255-10218_LPS-IL_24.raw24 LPS Lipidomics
SA194139258-9785_LPS-IL_24.raw24 LPS Lipidomics
SA194140256-8473_LPS-IL_24.raw24 LPS Lipidomics
SA194141264-9855_CON-IL_48.raw48 CON Lipidomics
SA194142260-9609_CON-IL_48.raw48 CON Lipidomics
SA194143262-9610_CON-IL_48.raw48 CON Lipidomics
SA194144261-9852_CON-IL_48.raw48 CON Lipidomics
SA194145263-10336_CON-IL_48.raw48 CON Lipidomics
SA194146265-10218_LPS-IL_48.raw48 LPS Lipidomics
SA194147266-8473_LPS-IL_48.raw48 LPS Lipidomics
SA194148267-10008_LPS-IL_48.raw48 LPS Lipidomics
SA194149269-10103_LPS-IL_48.raw48 LPS Lipidomics
SA194150268-9785_LPS-IL_48.raw48 LPS Lipidomics
SA194151211-9852_CON-IL_4.raw4 CON Lipidomics
SA194152210-9609_CON-IL_4.raw4 CON Lipidomics
SA194153214-9855_CON-IL_4.raw4 CON Lipidomics
SA194154213-10336_CON-IL_4.raw4 CON Lipidomics
SA194155212-9610_CON-IL_4.raw4 CON Lipidomics
SA194156216-8473_LPS-IL_4.raw4 LPS Lipidomics
SA194157218-9785_LPS-IL_4.raw4 LPS Lipidomics
SA194158217-10008_LPS-IL_4.raw4 LPS Lipidomics
SA194159215-10218_LPS-IL_4.raw4 LPS Lipidomics
SA194160219-10103_LPS-IL_4.raw4 LPS Lipidomics
SA194161222-9610_CON-IL_8.raw8 CON Lipidomics
SA194162220-9609_CON-IL_8.raw8 CON Lipidomics
SA194163224-9855_CON-IL_8.raw8 CON Lipidomics
SA194164223-10336_CON-IL_8.raw8 CON Lipidomics
SA194165221-9852_CON-IL_8.raw8 CON Lipidomics
SA1941669855CON-IL-8_NEG.raw8 CON Metabolomics
SA19416710336CON-IL-8_NEG.raw8 CON Metabolomics
SA1941689852CON-IL-8_NEG.raw8 CON Metabolomics
SA1941699609CON-IL-8_NEG.raw8 CON Metabolomics
SA1941709610CON-IL-8_NEG.raw8 CON Metabolomics
SA194171227-10008_LPS-IL_8.raw8 LPS Lipidomics
SA194172229-10103_LPS-IL_8.raw8 LPS Lipidomics
SA194173228-9785_LPS-IL_8.raw8 LPS Lipidomics
SA194174226-8473_LPS-IL_8.raw8 LPS Lipidomics
SA194175225-10218_LPS-IL_8.raw8 LPS Lipidomics
SA1941768473LPS-IL-8_NEG.raw8 LPS Metabolomics
SA1941779785LPS-IL-8_NEG.raw8 LPS Metabolomics
SA19417810103LPS-IL-8_NEG.raw8 LPS Metabolomics
SA19417910008LPS-IL-8_NEG.raw8 LPS Metabolomics
SA19418010218LPS-IL-8_NEG.raw8 LPS Metabolomics
SA194098QC_3_NEG.raw. . Metabolomics
SA194099QC_1_NEG.raw. . Metabolomics
SA194100QC_2_NEG.raw. . Metabolomics
SA194078202-9610_CON-IL_0.raw- CON Lipidomics
SA194079204-9855_CON-IL_0.raw- CON Lipidomics
SA194080200-9609_CON-IL_0.raw- CON Lipidomics
SA194081201-9852_CON-IL_0.raw- CON Lipidomics
SA194082203-10336_CON-IL_0.raw- CON Lipidomics
SA19408310336CON-IL-0_NEG.raw- CON Metabolomics
SA1940849610CON-IL-0_NEG.raw- CON Metabolomics
SA1940859852CON-IL-0_NEG.raw- CON Metabolomics
SA1940869855CON-IL-0_NEG.raw- CON Metabolomics
SA1940879609CON-IL-0_NEG.raw- CON Metabolomics
SA194088206-8473_LPS-IL_0.raw- LPS Lipidomics
SA194089209-10103_LPS-IL_0.raw- LPS Lipidomics
SA194090208-9785_LPS-IL_0.raw- LPS Lipidomics
SA194091205-10218_LPS-IL_0.raw- LPS Lipidomics
SA194092207-10008_LPS-IL_0.raw- LPS Lipidomics
SA19409310008LPS-IL-0_NEG.raw- LPS Metabolomics
SA1940948473LPS-IL-0_NEG.raw- LPS Metabolomics
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 103

Collection:

Collection ID:CO002138
Collection Summary:Blood was collected via coccygeal venipuncture after the morning milking during the baseline period and at -0.5, 0, 4, 8, 16, 24, and 48 h, relative to saline or LPS administration. Plasma samples were incubated on ice for 30 min before centrifugation.
Collection Protocol ID:N/A
Collection Protocol Filename:Collection_Protocol.docx
Collection Protocol Comments:N/A
Sample Type:Blood (plasma)
Collection Method:Blood collection using venipuncture needle
Collection Location:Coccygeal venipuncture
Collection Frequency:At interval of -0.5, 0, 4, 8, 16, 24, and 48 h respectively
Collection Duration:1 min
Volumeoramount Collected:10ml
Storage Conditions:-20℃
Collection Vials:10 ml blood vial
Storage Vials:Eppendorf tubes 2ml
Collection Tube Temp:4°C

Treatment:

Treatment ID:TR002157
Treatment Summary:Sterile saline (CON; n = 5) or 2) LPS (0.375 μg of LPS/kg of BW in sterile saline; Escherichia coli O55:B5; Sigma Aldrich, St. Louis, MO; n = 5)
Treatment Protocol ID:N/A
Treatment Protocol Filename:N
A

Sample Preparation:

Sampleprep ID:SP002151
Sampleprep Summary:Untargeted lipidomics samples were prepared by dissolving in dicholormethane/ methanol ( MeOH; 2:1). Untargeted metabolomics was done by centrifugation, samples were re-suspended with 60% ACN prior to analysis. FOR details please refer to publication Wang et al 2022.

Combined analysis:

Analysis ID AN003362
Analysis type MS
Chromatography type Reversed phase
Chromatography system Vanquish UHPLC system
Column Accucore C30 (150 x 2.1mm,2.6um)
MS Type ESI
MS instrument type Single quadrupole
MS instrument name Thermo Q Exactive HF hybrid Orbitrap
Ion Mode UNSPECIFIED
Units Normalized ion intensity

Chromatography:

Chromatography ID:CH002488
Chromatography Summary:Chromatographic separation was performed on a Vanquish UHPLC system with an Accucore C30, 2.6 μm column (2.1 mm id × 150mm) coupled to a Q Exactive™ Hybrid Quadrupole-Orbitrap High Resolution Mass Spectrometer (Thermo Fisher Scientific, San Jose, CA) and generated data was processed using LipidSearch™ software version 4.1 (Thermo Scientific),
Methods Filename:Genenral_method_for_Untargeted_Metabolomics_Mar2020.docx
Instrument Name:Vanquish UHPLC system
Column Name:Accucore C30 (150 x 2.1mm,2.6um)
Chromatography Type:Reversed phase

MS:

MS ID:MS003131
Analysis ID:AN003362
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Single quadrupole
MS Type:ESI
MS Comments:Please refer to publication Wang et al 2022.
Ion Mode:UNSPECIFIED
  logo